StemCell Therapy

Tuesday, June 30, 2020 3:17 a.m. EDT by Thomson Reuters

By Kate Kelland

LONDON (Reuters) - A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators.

The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known as the COPCOV trial after hydroxychloroquine was found in another British trial to have no benefit as a treatment for patients already infected with COVID-19, the disease caused by the new coronavirus.

TheCOPCOVstudy was paused pending review after the treatment trial results.

It is a randomised, placebo-controlled trial that is aiming to enrol 40,000healthcare workers and other at-risk staffaround the world, and is being led by the Oxford University's Mahidol Oxford Tropical Medicine Research Unit(MORU) in the Thai capital, Bangkok.

U.S. President Donald Trump said in March hydroxychloroquine could be a game-changer and then said he was taking it himself, even after the U.S. regulator, the Food and Drug Administration (FDA), advised that its efficacy and safety were unproven.

The FDA later revoked emergency use authorisation for the drugs to treat COVID-19, after trials showed they were of no benefit as treatments.

But White, who is co-leadng the COPCOV trial, said studies of the drugs as a potential preventative medicine had not yet given a conclusive answer.

"Hydroxychloroquine could still prevent infections, and this needs to be determined in a randomised controlled trial," he said in a statement. "The question whether (it) can prevent COVID-19 or not remains as pertinent as ever."

White's team said recruitment of British health workers would resume this week, and said plans were under way for newsites in Thailand and Southeast Asia,Africa and South America.Results are expected by the end of this year.

(Reporting by Kate Kelland, editing by Paul Sandle and Timothy Heritage)

Read more:
Global COVID-19 prevention trial of hydroxychloroquine to resume - WNWN-FM

Launches First-in-Kind Reimbursed Virtual Fitness Program for GO365 Members

NEW YORK, June 29, 2020 /PRNewswire/ --Virtual Health Partners (VHP), an innovator in cost-effective virtual health and wellness solutions, and Gold's Gym, the world's trusted fitness authority, today announce the launch of their highly comprehensive live virtual fitness and nutrition programming and on-demand services to members ofGO365, a Humana brand, powered by Concierge Health's Connected Ecosystem.

VHP empowers and incentivizes GO365 members to become more active and take control of their health and fitness goals by tracking participation and progress to achieve rewards.

In partnership with Gold's Gym, VHP streamlines the home workout process by granting members exclusive on-demand classes, live workouts, nutrition, training tips, progress tracking, accountability groups, and 24/7 access to Gold's Gym fitness experts. This virtual system fills in the gaps that are left by the new regulations imposed on the fitness industry by COVID-19, providing a sense of community many people need to stay inspired and motivated."

"This pandemic has accelerated the need to provide consumers a fully omnichannel fitness and wellness offering, both in our clubs and at home," shares Adam Zeitsiff, President & CEO of Gold's Gym. "Virtual Health Partners enables us to deliver world-class fitness, training, and class variety that Gold's Gym is known for the last 50+ years, straight into GO365's member's home. Leveraging Concierge Health's ecosystem, we can provide an end to end solution making data collection from the home seamless for the members to receive their reward benefits."

"Our model provides a scalable and customizable solution to fit any of our partners' needs all thru a turnkey HIPAA and Privacy compliant platform," states Jillian Bridgette Cohen, VHP Co-Founder, and CEO. "Our extensive understanding across multiple sectors has enabled us to build broad integration capabilities within the marketplace, which, in partnership with Gold's Gym, has allowed us to help merge the fitness, medical, and insurance industry cohesively."

GO365 members can get started by going to https://virtualhealthpartners.com/go365golds/to get registered and started.

AboutVirtual Health PartnersVirtual Health Partners (VHP) is an innovator in cost-effective health and wellness, focusing on live, virtual nutrition, fitness and lifestyle modification within a contained ecosphere of support. Offered exclusively through networks of participating partners including insurers, hospital systems, physicians, corporations, pharmaceutical, medical device, fitness and nutrition companies, VHP's Business-to-Business-to-Consumer (B2B2C) model provides a SaaS and PaaS solution that is scalable and can be white labeled to fit partners' needs. Through the private, HIPAA compliant platform, VHP provides its partners with a turnkey solution for clients in the areas of weight loss and weight loss procedures, metabolic syndrome, oncology, women's health, digestive diseases, cardiac rehab, preventative medicine, plastic surgery and general wellness.www.virtualhealthpartners.com

About Gold's GymGold's Gym has been the world's trusted fitness authority since 1965. From its beginning as a small gym inVenice,California, Gold's Gym has grown into a global icon with nearly 700 locations in 29 countries. Featuring personalized transformation plans, state-of-the-art equipment, certified personal trainers, a diverse group exercise program and a supportive, motivating environment, Gold's Gym delivers the most dynamic fitness experience in the industry. The Gold's Gym experience includes GOLD'SSTUDIO which gives members access to boutique-style classes like GOLD'S FIT, GOLD'S BURN and GOLD'S CYCLE, all under one roof along with GOLD'S AMP, the first digital personal training app from a brick-and-mortar gym. More than a gym, Gold's Gym combines coaching, community and more than 50 years of fitness expertise to help people around the world achieve their potential through fitness. For more information, visitwww.goldsgym.comor follow Gold's Gym onFacebook,InstagramandTwitter.

Story continues

Original post:
Virtual Health Partners Teams Up With GOLD'S GYM To Instantly Give Millions Better Health On Demand - Yahoo Finance

Sleep paralysis is the feeling of being unable to move when you're falling asleep or waking up. That's because people experiencing sleep paralysis are awake and alert, but unable to move their muscles.

The condition is relatively common, says Gonzalo Laje, MD, director of Washington Behavioral Medicine Associates in Chevy Chase, Maryland. Roughly 8% of people in the U.S. will experience sleep paralysis at least once in their lives.

"The body paralyzes itself during REM sleep, so we don't act out our dreams and hurt ourselves or our bedpartners," says Nate Watson, MD, co-director of the University of Washington Medicine Sleep Center.

Advertisement

Sleep paralysis can occur at two points, says Patricia Celan, MD, a psychiatry resident at Dalhousie University in Nova Scotia, Canada.

However, many people with sleep paralysis develop anxiety because the episodes can be frightening. In some cases, this can even cause insomnia if people feel afraid to sleep, Laje says. If that happens or if episodes become more frequent, it's time to seek professional help.

"There is no definitive cure for sleep paralysis, but if someone is bothered by it, there are actions that can be taken to reduce its risk of occurring," Celen says.

In fact, people who say they have good sleep quality are less likely than those who have bad sleep quality to experience sleep paralysis.

"Treating sleep paralysis involves optimizing sleep habits," Celen says. "That means improving sleep hygiene so you can fall asleep more easily and get a full night's rest."

If that's the case, it's most important to treat those conditions, like sleep apnea or depression, as it can help prevent sleep paralysis and improve your overall health.

Knowing more about sleep paralysis like the fact that it's common and not actually harmful can make occurrences easier to deal with and help reduce anxiety about the condition.

Some types of CBT like CBT-I, which is used to treat insomnia also teach relaxation techniques that are useful for improving your sleep hygiene and getting better sleep.

There is some early research that selective serotonin reuptake inhibitors (SSRIs), commonly used to treat depression, can help treat sleep paralysis.

If you experience sleep paralysis once, it's not an immediate cause for concern, but you should focus on improving your quality of sleep.

"Although scary when it occurs, sleep paralysis is generally brief, self-limited, and does not indicate the presence of narcolepsy," Watson says. "When it occurs, it is a sign that your sleep may not be healthy."

Read the rest here:
What causes sleep paralysis and how to reduce your risk - Business Insider India

Many veterinarians will agree that preventive care is the secret to keeping pets healthy and happy at all times.However, achieving this can prove to be a daunting task especially when your clients do not believe it to be true.It is for this reason that most veterinarians are looking forward to helping clients understand the significance of preventative healthcare and the value of making visits to the veterinarian.One professional who is already raising the bar of quality and service in veterinary medicine is Miamis Dr. Xavier Meaux.

Born and raised in Puerto Rico, Dr. Xavier Meaux has greatly transformed the veterinary industry.After receiving his Bachelors in Animal Science from Purdue University in 2002, he went on to graduate from Tuskegee University School of Veterinary Medicine in 2006.It is after his graduation that he started his quest of making the veterinary industry better.

After amassing years of experienceas a relief emergency veterinarian, Dr. Meaux together with Pedro Armstrong, DVM, DACVIM, decided to start a company called Mobile Pet Imaging.This is after witnessing how patients with neck discomfort find it hard to eat, yet most radiologists and doctors would think twice before putting the patient in a CT scanner.

Mobile Pet Imaging is already changing the veterinary landscape by making imaging technology more accessible to patients having neck discomfort and others with less daunting features such as floppy ears.What is even more fascinating is the fact that the company delivers robotic high-definition CT (HD CT), fluoroscopy, and IR straight to the doorsteps of veterinary facilities. For Dr. Meaux, this is just but a new beginning for veterinarians with many things expected in the future.

Originally posted here:
On the road with Dr. Xavier Meaux - Jill Lopez

Verdict Medical Devices caught up with Vectorious medical director Dr Leor Perl to learn more about the V-LAP system. Credit: Vectorious The V-LAP is a miniature device of 2.5 millimetres in diameter which anchors to the interatrial septum. Credit: Vectorious Data from V-LAP is transmitted out into an external belt, which sends the information to the cloud. Credit: Vectorious

Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.

Many people, both healthy and sick, use wearable devices to monitor their body and track their health. Its common knowledge that the readings from these devices wont be the most accurate in the world, but under the right circumstances they can provide interesting titbits about how a person is doing physically. But when it comes to monitoring serious health conditions, patients need something more heavy-duty.

Around 26 million people worldwide live with heart failure, where the muscles of the heart struggle to pump blood around the body. All people with chronic heart failure will need monitoring, but it can be hard to predict when adverse events arising from the condition will occur until theyre already happening.

Enter Vectorious. The Israeli medtech company has developed the worlds first in-heart computerised device, the V-LAP. V-LAP is a miniature, wireless, battery-free microcomputer that rests directly on the hearts interatrial septum and provides precise pressure readings to patients and clinicians at the push of a button.

The data is passed through an accompanying portable belt, which wirelessly syncs with the implant and then transmits information from the device securely into the cloud. Using artificial intelligence (AI), clinicians can see a preventative analysis of any heart anomalies, detecting potential risks before they occur and helping to prevent them.

Verdict Medical Devices caught up with Vectorious medical director Dr Leor Perl to learn more about the implantable blood pressure monitor.

Chloe Kent: How does the V-LAP device work?

Leor Perl: The V-LAP is silent and does not work throughout the day unless it is being activated by an external unit. The external unit does two main things one, it transmits energy by inductive coupling to the implant, creating a situation where the implant begins measuring pressure. It can give you information on the heart rate, temperature, pressure rating. It holds a lot of information because its a high-fidelity, high-resolution waveform each beat.

The implant has a computer within it, theres an AC chip, and it corrects for drift, which is a major issue with biological tissues in general. The data is then transmitted out into the external belt, which sends the information to the cloud. Clinicians can then get a pressure reading remotely, with heart rate and the temperature and so on, anywhere in the world.

CK: What is this experience like for a patient?

LP: Its a tremendous change. The patient does have to undergo the implantation procedure. It takes minutes; its a minimally invasive procedure. We get some local anaesthesia and we go through the femoral vein via a needle into the heart and implant it there. Its a miniature device, its 2.5 millimetres in diameter, and its anchored to the interatrial septum, so it just sits there like any other device thats being implanted in the heart.

Assuming the patient is compliant, measuring pressure once or twice a day, this data is transmitted to the team that takes care of these patients. Remember, these are patients with heart failure, who have a very high risk of being admitted to hospital once again. Heart failure is the number one condition in terms of the risk of readmissions. These are patients who come in and out of the hospitals, usually with severe symptoms of shortness of breath, they feel like they basically are being strangled to death. Its a very scary, uncomfortable, bad place to be at when they become admitted. This device from now on will foresee these acute exacerbations in heart failure where there is a risk for an acute heart failure event like that.

CK: Would you say your product represents a shift in how to approach patient care?

LP: Its a whole new world. Its a completely different way of treating these patients. Imagine trying to balance patients with diabetes without having glucose monitors. Treating patients with heart failure without having knowledge of the pressure within the cardiovascular system has been shown scientifically to be inaccurate. What they do presently is they measure weight, they look at symptoms and thats how medications have been titrated. Now we have objective, actionable data that shows us how to treat these patients.

CK: How do you feel the Covid-19 pandemic has impacted remote monitoring technologies like yours?

LP: Like many other crises in the past, humanity is going to grow. One of the things in the medical device world that I think people are appreciating now is that patients dont necessarily have to come into the hospital for some of the things that weve been doing. In fact, its probably better if they stay at home, with or without the pandemic. Thats been the case that weve been trying to make for years, because admissions in the US and the UK are very expensive, and it can actually be dangerous to come into the hospital when you have heart failure or other chronic diseases.

Theres been a change in the reimbursement strategies of many of the healthcare organisations to try and mitigate some of this flow into the hospital. Some physicians and some hospitals are looking at admissions actually, as a complementary event to the maintenance of care that we can perform at home.

CK: What do you see as the future of remote care post-pandemic?

LP: Things are not going to be what they used to be. The whole strategy of the hospital is going to change. In the world of telemonitoring, I think this is going to be the dawn of remote patient care. We have to realise that not all wearables and remote data is useful. To actually use data to care for these patients, physicians have to go through regulated medical devices that have been shown to pinpoint valuable information and we can treat these patients according to that data, which has been scientifically proven and legally regulated.

I think that 10 years from now, many chronic conditions, and maybe some acute ones, will be diagnosed, monitored and treated according to multiple sensors. Patients with chronic lung disease, cancer, chronic pain, neurological conditions these patients can benefit a lot from data that comes from remote monitoring. Thats going to be a huge shift because it requires infrastructure, it requires new training for the medical staff, but its going to make life easier and safer for patients.

CK: So youre seeing medicine shifting more towards prevention than cure?

LP: Im just going to throw in a crazy thought. Imagine a future where 20 years from now all babies born in the UK and Israel and the US are implanted with completely safe, durable and efficient sensors that can let you know when theyre at risk for things like sudden infant death syndrome, or when theyre having an allergic reaction or fever. And then as you become older, you go in during your puberty to get your puberty chip implanted and that lets you know when your cholesterol goes up, or if youre going into a risk category for diabetes. It sounds crazy, but I do think that our children will have that opportunity.

CK: I can see a lot of people being very averse to what youve suggested there how would you convince them its a good idea?

LP: Oh, yeah, therell be some pushback. It has to be regulated, has to be safe. But this is not to invade privacy and to know where you are, but to have information on disease to protect us.

Read more here:
Developing the world's first implantable blood pressure monitor - Medical Device Network

OSWEGO Public health touches all levels of the community; from pre-natal health care to hospice care, from the food we eat to the water we drink, from rabies control to emergency preparedness. With a variety of programs focused on these issues and more, the Oswego County Health Department strives to promote good health and wellness practices and ensure that communities throughout the county are thriving.

The county first established its public health nursing division in the 1960s, so it has a long tradition of delivering quality services to residents. Then, as now, its highly trained staff is on-call to provide skilled care on a variety of fronts, including preventative health care.

We are lucky to have these people on the front lines of the COVID-19 pandemic in our county, said Oswego County Legislature Chairman James Weatherup, District 9. Not all counties have staff with this level of training and expertise in epidemiology. They work tirelessly every day to manage the countys response to the coronavirus while adhering to guidance set forth by the state.

Oswego County Legislator James Karasek, District 22, chairman of the Oswego County Health Committee agreed. Residents can be assured we have an excellent team responding to this crisis. Not only is our public health director a trained epidemiologist, but our nursing staff also has decades of combined experience in preventative health care.

Leading the team is Oswego County Public Health Director Jiancheng Huang. He arrived in Oswego County in 2012 after several years with the Maine Immunization Program of the Maine Centers for Disease Control (CDC); first as an epidemiologist, then as the programs director. A Harvard graduate with a degree in population and international health, Huang is experienced in biomedical research and has served various regional and national workgroups to promote the understanding of infectious disease and immunization.

Epidemiology is an important cornerstone of public health, said Huang. It is an evidence-based science that provides the foundation of our decision-making process. Only with thorough investigation and unbiased analysis can we identify cause and effect, and then determine the best course of action that is, the most effective and appropriate responses to public health issues.

It is these very life-saving practices that brought him into the field of public health.

I realized that as a doctor, I could only treat patients one by one, said Huang. But as a member of a public health agency, we can address many of the broader issues that impact the well-being of our residents and effect real change. In this way, the whole of the population is the patient and we can help educate and encourage people to improve the overall health of the community. This is what epidemiology is.

Choosing to work in a rural location is no accident either. Through his internship in a rural hospital, he recognized the need for quality public health practices in that setting and knew he could be the most help there.

While Huang has largely worked with rural populations, he nevertheless has had experience with major public health crises before this, including severe acute respiratory syndrome (SARS) and H1N1.

I worked with the SARS outbreak in 2003 and the H1N1 pandemic in 2009, said Huang. COVID-19 is perhaps the most challenging of the three in its effect on public health. None of the past outbreaks were at a scale that is close to this.

That being said, he continued. I have complete faith in the capabilities of our epidemiology team and in the skills and experience of our entire staff. Public health relies on teamwork. With the dedication of our health department team and the support of our community, I know that we will all get through this difficult time together.

Over the years, Oswego County has made a significant investment in its staff to increase their epidemiology capabilities.

Tina Bourgeois is a senior LPN with 30 years of experience focused on investigating communicable diseases and promoting immunizations.

COVID-19 hasnt really changed what I do most days, said Bourgeois. Every year, I investigate hundreds of reportable communicable diseases through contact tracing. The thing thats new is the virus itself, so were learning more about that every day.

When a patient tests positive for coronavirus, Bourgeois contacts that person to go over the results. She said that can be difficult because there is a lot of fear, confusion and uncertainty about this new virus.

Many people are scared, they dont know what to expect, she said. As an investigator you have to be kind. Listen to their concerns and give them some reassurance. Be honest and answer all their questions as best as you can. When I talk to people, I make sure they understand their diagnosis and are receiving the proper treatment so they can get well.

Investigators also ask if patients have been in contact with other people so they can determine if others may have been exposed or need treatment. We have to reduce the spread of this disease, so its not uncommon for me to have to tell people they need to stay home for a period of time, said Bourgeois. Well review work restrictions or talk about how to prevent exposing other family members in the home to the disease.

Huang said, Tinas experience is one of the strengths of this team. She asks so many good, detailed questions. We learn a lot from her about contact tracing.

Oswego County has long encouraged the use of educational and career incentives where possible to better develop an employees capabilities.

Chantel Eckert, DNP, RN, has repeatedly taken on the challenge of higher education to the benefit of the countys health department. She said, Advanced education has provided me with a solid foundation in clinical prevention and population health which has been instrumental in helping me see the big picture of this pandemic.

Eckert serves as program manager for Healthy Families Oswego County and, as a supervising public health nurse, continues to assist with coverage of the health departments nursing division. In the wake of the current pandemic, this includes helping with the nursing phone bank by answering medical questions and concerns from the public. She also exercises her analytical skills to track the virus activity.

The majority of my time is spent collecting and analyzing data related to the coronavirus, said Eckert. Using a systematic approach, I can identify trends with the virus and provide accurate and timely information to our team. This helps them with public reporting, contact investigations and, most importantly, determining the appropriate prevention and control measures to implement to reduce the spread of the disease.

Huang said, This is the science of epidemiology. It is how we respond to the pandemic and keep our residents safe. Scholarly data analysis is a critical skill during a public health crisis. Chantels doctoral education is a valuable asset to the team.

Jodi Martin, RN, BSN, continues along the path of higher learning to further enhance her skills and capabilities with the health department. She completed a Health Leadership Fellow

Program last year and is now pursuing her masters degree in nursing with an emphasis on public health.

My fellowship and current studies, combined with a decade-long career in public health have helped prepare me for this challenge, said Martin. I view the data in a new way which gives me a better understanding of public health activities and improves my ability to respond to this unprecedented crisis.

Martin, also a supervisory public health nurse, works with many public health programs in the departments preventative care unit, including communicable disease surveillance and the immunization program.

Last summer, Oswego County saw a spike in hepatitis A cases, the highest in the state. Im very proud of our work in identifying the high-risk populations and finding creative ways to reach out to them, she said. We were able to complete difficult contact investigations and provide vaccinations to at-risk individuals.

Huang added, Our team was very successful in containing this disease and received praise from the state Department of Health for our hard work. In addition, several other counties in the state asked us to share our disease containment activities. Jodis creative thinking was an integral part of that success. She continues to bring a fresh perspective on public health to the team.

Dr. Christina Liepke, medical director for Oswego County, brings nearly two decades of experience in family medicine to the team. A graduate of Upstate Medical University, Dr. Liepke served on the Oswego County Board for Health for several years before being named medical director for Oswego Countys Health Department and Hospice Program in 2014. She also maintains a family medicine practice with Port City Family Medicine.

The COVID-19 pandemic is a humbling experience; unprecedented in its magnitude, said Dr. Liepke. What I have learned from it is that we have an amazingly generous community and dedicated staff who are unwavering in their duties. Through it all, everyone on our health department team, from our nurses to the public health director, works day after day without complaint to safeguard our residents. It is a compassionate, collaborative and creative team qualities we need when facing such a unique disease and I am humbled and thankful to work with such amazing people.

Huang agreed, We have a wonderful team managing Oswego Countys response to the COVID-19 pandemic. Dr. Liepkes role is important to continue the countys long tradition of health care services and activities. Epidemiology is another branch of medicine and she brings great insights to our decision-making processes. Her input is indispensable to the entire team.

For more information about Oswego Countys COVID-19 response, go to oswegocounty.com or health.oswegocounty.com/covid-19. Additional questions can be directed to the Oswego County Health Department COVID-19 Hotline at 315-349-3330 from 8:30 a.m.-4 p.m. Monday through Friday. For information about emotional supports, visit the Oswego County Department of Social Services Division of Mental Hygiene at http://www.oswegocounty.com/mentalhygiene.

View original post here:
'Teamwork Makes the Dream Work' behind the front lines with the Oswego County Health Department - NNY360

Throughout the past week, Ohio Governor Mike DeWine was joined by Lt. Governor Jon Husted, and provided updates on Ohio's response to the COVID-19 pandemic, as well as state initiatives.

On Tuesday, Governor DeWine endorsed Wright-Patterson Air Force Base (WPAFB) and the surrounding Dayton region as the ideal location for the new United States Space Command headquarters.

"Wright-Patterson Air Force Base and the Dayton region would be excellent hosts for the U.S. Space Command's new headquarters," said Governor DeWine. "This area is already home to the National Air and Space Intelligence Center, Air Force Research Laboratory, Air Force Life Cycle Management Center, and Air Force Material Command. It's a powerful combination and a synergy that you can't find anywhere else."

In a letter sent to the Assistant Secretary of the Air Force, Governor DeWine endorsed the nomination submitted by Beavercreek Mayor Bob Stone. A letter signed by 22 area mayors and four county commission presidents was also submitted expressing mutual support for the Dayton region to be considered for the permanent U.S. Space Command headquarters.

The Department of the Air Force, in coordination with the Office of the Secretary of Defense, announced in May that it would accept nominations for the headquarters' location based on specific criteria. WPAFB and the Dayton region met all of the screening requirements.

If selected, the new headquarters could bring up to 1,400 personnel to Ohio.

Copies of the letters sent can be found at governor.ohio.gov.

Also on Tuesday, Governor DeWine announced two public awareness campaigns aimed at spreading awareness of COVID-19 prevention measures that impact the well-being of Ohioans and the Ohio economy.

The messages of these ads are clear, said Governor DeWine. Ohioans, by continuing to practice good prevention, can do two things at once, help stop the spread of COVID-19, and responsibly and safely get back to work.

The first campaign, called I Believe, focuses on real Ohioans and the prevention measures they take to prevent the spread of COVID-19. These 15-second ads, provided by the Ohio Department of Health, will air for three weeks on broadcast, cable, and social media across the state. The PSAs feature two Ohio healthcare professionals.

I Believe (1)

Dr. Kevin Sharrett, MD, is a primary care physician with Cedarville and Jamestown Family Practice. He is the Medical Director for the Greene County Health Department and the Medical Director for Rural Health for the Kettering Health Network. He has served as the Greene County Coroner since 1997. A graduate of Wright State University School of Medicine, Dr. Sharrett also is a farmer and has dedicated his career to serving rural Ohioans.

I Believe (2)

Shareece Mashiska, RN, has been caring for patients in the Youngstown/Warren communities for more than 15 years. A nurse manager at Mercy Health St. Elizabeth Youngstown Hospital, Shareece began her career in the intermediate unit at Mercy Health St. Joseph Warren Hospital before becoming an intensive care nurse working both in-patient and on Mercy Healths mobile intensive care unit. Currently residing in the Mahoning Valley, Shareece believes social distancing remains a critical piece of keeping our communities safe, which includes her own husband and three children.

Up to All of Us

The second campaign, called Up to All of Us, focuses on the importance of taking proper preventative precautions, such as maintaining social distance and washing hands, to get Ohioans back to work and Ohio's economy working again. The ad, provided by the Ohio Bureau of Workers Compensation, will air for three weeks on broadcast and cable television and features an emergency room physician and a local restaurant owner and operator.

Laura Espy-Bell, MD, MHA, FACEP is a board-certified Emergency physician and a native of Columbus, Ohio. She is a graduate of Spelman College in Atlanta, GA where she received her Bachelor of Arts in Economics in 2003. Dr. Espy-Bell received her Master of Healthcare Administration (MHA) from the University of North Carolina at Chapel Hill in 2005. Dr. Espy-Bell graduated from The Ohio State University College of Medicine in 2011. Dr. Espy-Bell has been an active member of the OhioHealth medical staff for the past 6 years as an Emergency Medicine attending physician with Mid-Ohio Emergency Services (MOES) and has provided quality health care in several OhioHealth emergency departments.

Gary Callicoat is the president of Rusty Bucket Restaurant and Tavern, which he first opened in 2002. Reflecting a long record of giving back to the hospitality industry, Callicoat serves on the board of the Ohio Restaurant Association (ORA) and is equally committed to supporting charitable causes of the communities in which he does business. He is also on the board of the ORAs Education Foundation.

FIREWORKS

Lt. Governor Husted noted that Independence Day fireworks shows can proceed, but large gatherings are still prohibited at this time. He encouraged any community that plans on holding a fireworks event to do so safely. Spectators are encouraged to find ways to celebrate the Fourth of July in small groups, such as by watching displays from their porches, backyards, or cars.

CRIMINAL JUSTICE GRANTS

Governor DeWine announced the first round of funding being distributed to local criminal justice entities as part of the Coronavirus Emergency Supplemental Funding Grant.

Approximately $2.1 million will be awarded to a total of 65 local criminal justice agencies including law enforcement, probation/parole offices, corrections agencies, courts, and victim service providers.

The funding can be used toward COVID-19 expenses such as cleaning supplies, PPE, and medical supplies like thermometers. The funding will also be used to pay for technology upgrades that are needed for teleworking or other virtual services.

A complete list of grant recipients can be found at coronavirus.ohio.gov.

A total of nearly $16 million was awarded to Ohio's Office of Criminal Justice Services (OCJS) for this program as part of the CARES Act. OCJS continues to process other grant applications theyve already received and are still accepting new applications from agencies that have not yet requested funding.

More information on how to apply can be found at http://www.ocjs.ohio.gov.

On Wednesday, Governor DeWine, First Lady Fran DeWine, and Lt. Governor Husted visited Lordstown Motors for a first look at the 2020 Endurance All-Electric Pickup Truck.

On Thursday, Governor DeWine invited President and CEO of UC Health Richard P. Lofgren, MD, MPH, FACP to give an update on the status of COVID-19 in Hamilton County and the surrounding areas.

The effective reproductive ratio, also known as R naught, measures how many people will be infected by a sick individual. The R naught had reached 2.4 in that region in April. In recent weeks, the R naught had declined to below one. However, in the last 10 days, the R naught has doubled over the last 10 days in the Cincinnati region.

Dr. Lofgren explained that the increase in cases is not only due to the tests being performed, but the increase shows there is a greater presence of the COVID-19 in the area, and it is spreading in the community. He said it serves as a reminder about the importance of wearing a mask in public, washing your hands, sanitizing frequently touched surfaces, and keeping social distance.

OHIO 2-1-1

Governor DeWine announced that the Ohio Department of Health will continue funding for the valuable 2-1-1 service as Ohio enters into the next phase of the COVID-19 pandemic.

2-1-1 is a phone service that connects thousands of Ohioans to local non-profit and government services for healthcare, food and meals, housing, transportation, mental health, and legal services.

At the beginning of the year, the service was available in 51 of Ohios 88 counties. When the pandemic began, Ohio EMA asked Ohio AIRS, the non-profit that governs Ohio 2-1-1, to provide service to the remaining 37 counties in Ohio, which happened in March.

Ohioans can also dial 877-721-8476 to get connected to 2-1-1.

Also on Thursday, Governor DeWine made several appointments to various boards and commissions, as well as two judicial appointments.

CURRENT OHIO DATA

As of Friday afternoon, there are 48,638 confirmed and probable cases of COVID-19 in Ohio and 2,788 confirmed and probable COVID-19 deaths. A total of 7,570 people have been hospitalized, including 1,904 admissions to intensive care units. In-depth data can be accessed by visiting coronavirus.ohio.gov.

For more information on Ohio's response to COVID-19, visit coronavirus.ohio.gov or call 1-833-4-ASK-ODH.

Read the original post:
Pandemic Response Week In Review - Vermilion Ohio - discoververmilion.org

Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on 12-14 July 2020. Data will include updated safety results from the phase IIIb STASEY study of Hemlibra (emicizumab) and new results from the phase III HAVEN 5 study of Hemlibra. Data will also include insights into the impact of living with haemophilia A. Spark Therapeutics (a member of the Roche Group) will also present data from the initial dose cohorts of its phase I/II SPK-8011 gene therapy study.

We are excited to share updated data from our combined haemophilia A programme at this years virtual ISTH 2020, said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. These data exemplify our efforts to increase our knowledge and capabilities in haemophilia A, including in the context of gene therapy, with the goal of advancing care and providing innovative treatment approaches for people living with this chronic condition.

SPK-8011 data presentationData from the initial dose cohorts of Sparks phase I/II SPK-8011 gene therapy study in haemophilia A will be presented at the congress. Updated data from five participants in the initial dose cohorts, who are up to 142 weeks post-vector infusion, show stable and durable factor VIII expression and a 91% reduction in annualised bleed rate (ABR). There is no evidence of decline in factor VIII expression after more than two years of follow up.1

These data indicate an acceptable safety profile, with no development of factor VIII inhibitors. Furthermore, they represent the longest stable expression of factor VIII following gene transfer and support the use of adeno-associated virus-mediated (AAV-mediated), liver directed gene therapy to achieve durable factor VIII expression for the treatment of haemophilia A.1

Key Hemlibra data presentationsData for Hemlibra will be featured in four poster presentations at the congress. This further supports the comprehensive body of clinical evidence available for Hemlibra, including from the HAVEN studies the most extensive clinical development programme in haemophilia A. This includes results from the second interim analysis of the phase IIIb STASEY study, evaluating the safety and tolerability of Hemlibra prophylaxis in people with haemophilia A with factor VIII inhibitors.

Further data from the STASEY study to be presented outline surgical experiences in the trial, as well as additional insights into the pharmacokinetics and pharmacodynamics profile of Hemlibra.

Roche will also share the first clinical data from the phase III HAVEN 5 study, evaluating the efficacy, safety and pharmacokinetics of Hemlibra in 70 people with haemophilia A with and without factor VIII inhibitors in the Asia-Pacific region. The study met its primary endpoint, demonstrating that Hemlibra prophylaxis dosed every week or every four weeks resulted in a statistically significant 96% (p<0.0001) reduction in the number of treated bleeds over time compared to those receiving no prophylaxis.5 In addition, all secondary bleed-related endpoints were met with clinically meaningful results. Overall, this study showed that Hemlibra was effective and well tolerated in this population.5 HAVEN 5 was conducted as part of the post-approval agreement with the Chinese health authorities to provide supportive data in people with haemophilia A in China, and was expanded to enrol patients from other Asia-Pacific countries.

Key data presentations on impact of haemophilia ARoche will also present two analyses providing insights into clinical outcomes from the CHESS II (Cost of Haemophilia in Europe: a Socioeconomic Survey-II) study evaluating disease burden in people with haemophilia A. The first analysis examines clinical outcomes in adults with mild, moderate and severe haemophilia A without factor VIII inhibitors, focusing on bleeding episodes and joint outcomes. Results show most people with mild and moderate haemophilia A (91% and 98% respectively) did not receive prophylaxis and the majority of these experienced one or more bleeds (74% and 85% respectively).6 These data demonstrate the potential treatment needs in these populations, and the clinical burden on those living with mild and moderate haemophilia A. Additional data from the CHESS II study explores the correlation between bleed frequency and physical activity levels in the same patient population, suggesting there is a correlation between the two.7

Key abstracts from Roche and Spark that will be presented at ISTH can be found in the table below.

Follow Roche and Spark on Twitter via @Roche and @Spark_tx respectively, and keep up to date with ISTH 2020 Congress news and updates by using the hashtag #ISTH2020.

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Monday 13 July 2020, 10:39 - 10:51 EST

Virtual Meeting Room 2

Sunday 12 July 2020, 14:00 15:00 EST

Virtual Meeting Room 6

Sunday 12 July 2020, 11:03 - 11:15 EST

Virtual Meeting Room 3

Second of three presentations occurring in the session, State of the Art Session on Hemophilia and Rare Bleeding Disorders on Sunday 12 July 2020, 8:45 10:00am EST

About Hemlibra (emicizumab)Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins involved in the natural coagulation cascade, and restore the blood clotting process for people with haemophilia A. Hemlibra is a prophylactic (preventative) treatment that can be administered by an injection of a ready-to-use solution under the skin (subcutaneously) once-weekly, every two weeks or every four weeks (after an initial once weekly dose for the first four weeks). Hemlibra was created by Chugai Pharmaceutical Co., Ltd. and is being co-developed globally by Chugai, Roche and Genentech. It is marketed in the United States by Genentech as Hemlibra (emicizumab-kxwh), with kxwh as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the US Food and Drug Administration.

About haemophilia AHaemophilia A is an inherited, serious disorder in which a persons blood does not clot properly, leading to uncontrolled and often spontaneous bleeding. Haemophilia A affects around 320,000 people worldwide,8,9 approximately 50-60% of whom have a severe form of the disorder.10 People with haemophilia A either lack or do not have enough of a clotting protein called factor VIII. In a healthy person, when a bleed occurs, factor VIII brings together the clotting factors IXa and X, which is a critical step in the formation of a blood clot to help stop bleeding. Depending on the severity of their disorder, people with haemophilia A can bleed frequently, especially into their joints or muscles.8 These bleeds can present a significant health concern as they often cause pain and can lead to chronic swelling, deformity, reduced mobility, and long-term joint damage.11 A serious complication of treatment is the development of inhibitors to factor VIII replacement therapies.12 Inhibitors are antibodies developed by the bodys immune system that bind to and block the efficacy of replacement factor VIII,13 making it difficult, if not impossible to obtain a level of factor VIII sufficient to control bleeding.

About Roche in haematologyRoche has been developing medicines for people with malignant and non-malignant blood diseases for over 20 years; our experience and knowledge in this therapeutic area runs deep. Today, we are investing more than ever in our effort to bring innovative treatment options to patients across a wide range of haematologic diseases. Our approved medicines include MabThera/Rituxan (rituximab), Gazyva/Gazyvaro (obinutuzumab), Polivy (polatuzumab vedotin), Venclexta/Venclyxto (venetoclax) in collaboration with AbbVie, and Hemlibra (emicizumab). Our pipeline of investigational haematology medicines includes idasanutlin, a small molecule which inhibits the interaction of MDM2 with p53; T-cell engaging bispecific antibodies, glofitamab and mosunetuzumab, targeting both CD20 and CD3; Tecentriq (atezolizumab), a monoclonal antibody designed to bind with PD-L1; and crovalimab, an anti-C5 antibody engineered to optimise complement inhibition. Our scientific expertise, combined with the breadth of our portfolio and pipeline, also provides a unique opportunity to develop combination regimens that aim to improve the lives of patients even further.About Roche and Spark Therapeutics gene therapy research in haemophilia AWe believe gene therapy has the potential to revolutionise medicine and improve the lives of patients with genetic and other serious diseases. Pairing Roches long-standing commitment to developing medicines in haemophilia with Spark Therapeutics proven gene therapy expertise brings together the best team of collaborators researching gene therapies in haemophilia A.

It is our aligned objective to develop gene therapies for haemophilia A that, with the lowest effective dose and the optimal immunomodulatory regimen, demonstrate safety, predictability, efficacy, and durability for patients.

About RocheRoche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve peoples lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the worlds largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the eleventh consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 61.5 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

References[1] George L et al. Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for >2 Years with Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A. [oral presentation no. OC03.5] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[2] Jimenez-Yuste V et al. Second Interim Analysis Results from STASEY Trial: A Single-arm, Multicenter, Open-Label, Phase III Clinical Trial to Evaluates the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII inhibitors. [poster no. 0958] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[3] Oldenburg J et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. NEJM 2017; 377:809-818.[4] Young G et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia A with inhibitors: results from the HAVEN 2 study. Blood 2018; 132 (Supplement 1): 632.[5] Wang S et al. A Randomized, Multicenter, Open-label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Persons with Hemophilia A in the Asia-Pacific region (HAVEN 5). [poster no. 0957] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[6] Nissen F et al. An Insight into Clinical Outcomes in Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHESS II Study [oral presentation no.OC 09.3] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[7] Nissen F et al. Associations Between Physical Activity Levels and Bleeding Frequency in People with Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHESS II Study. [poster no. 0943] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020[8] WFH. Guidelines for the management of haemophilia. 2012 [Internet; cited 2019 July]. Available from: http://www1.wfh.org/publications/files/pdf-1472.pdf.%5B9%5D Berntorp E, Shapiro AD. Modern haemophilia care. The Lancet 2012; 370:1447-1456.[10] Marder VJ, et al. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. 6th Edition, 2013. Milwakee, Wisconsin. Lippincott Williams and Wilkin.[11] Franchini M, Mannucci PM. Haemophilia A in the third millennium. Blood Rev 2013; 179-84.[12] Gomez K, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014; 12:s319-s329.[13] Whelan, SF, et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of haemophilia A patients. Blood 2013; 121:1039-48.

Roche Group Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com- Nicolas Dunant (Head)- Patrick Barth- Daniel Grotzky- Karsten Kleine- Nathalie Meetz- Barbara von Schnurbein

Go here to read the rest:
Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A - GlobeNewswire

Personalized medicine is tailoring of a treatment to a specific patient i.e. designing medicine treatment on the basis of diagnosis, disease condition, patient history, body physics, and other factors related to patients and diseases. Personalized medicine is also known as precision medicine, stratified medicine, or P4 medicine.

Read Report Overview https://www.transparencymarketresearch.com/personalized-medicines-market.html

In personalized medicine, diagnostic analysis is often conducted for selecting suitable and best treatments based on the patients genetic content or other molecular or cellular analysis. Personalized medicine has best response and highest safety margin to ensure enhanced patient care by allowing every patient to attain earlier diagnosis, risk assessment, and best treatment. Additionally, personalized medicine offers opportunities to improve health care by lowering overall treatment costs.

Rise in the prevalence of various types of cancer, affordability of personalized medicine therapy in cancer drugs and various other disease indications, less side-effects of personalized medicine therapy, high adoption in developed markets, and development of innovative drugs are factors driving the global personalized medicine market. However, high competition among existing market players, stringent government regulations regarding product approval, and lack of awareness among the rural population in developing economies are likely to hamper the market in the next few years.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=394

The global personalized medicine market is can be segmented based on product, application, distribution channel, and region. In terms of product, the market has been categorized into personalized medicine therapeutics, personalized medicine diagnostics, personalized nutrition & wellness, and personalized medical care. The personalized medicine therapeutics segment has been sub-categorized into pharmaceuticals, genomic medicine, and medical devices. The personalized medicine therapeutics segment is anticipated to hold the largest share of the global personalized medicine market during the forecast period, owing to rise in the prevalence of various types of cancer and chronic diseases.

Based on application, the global personalized medicine market has been divided into cancer management, infectious diseases, central nervous system (CNS) disorders, blood transfusion safety, coagulation therapy, diabetes, autoimmune diseases, cardiovascular diseases, neurology, and psychiatry. The cancer management segment is likely to hold the major share of the global market during the forecast period. Based on distribution channel, the market can be categorized into hospitals pharmacies, retail pharmacies, dietary care centers, and others. Rising prevalence of chronic diseases is likely to boost the market in the near future.

Request for Analysis of COVID19 Impact on Personalized Medicine Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=394

Geographically, the global personalized medicine market can be segmented into five major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. In terms of revenue, North America dominates the personalized medicine market, followed by Europe. The market in Asia Pacific and Latin America is developing. This trend is expected to continue during the forecast period as well.

Availability of large patient pool, expansion of the health care industry, and rise in government investments in improvement of health care are anticipated to propel the market in these regions. The personalized medicine market in countries such as Brazil, China, and India is projected to expand at a substantial growth rate during the forecast period, due to rise in awareness among people about usage of the personalized medicine therapy to treat various types of cancer and rapid innovations in personalized medicine for various other disorders.

Pre Book Personalized Medicine Market https://www.transparencymarketresearch.com/checkout.php?rep_id=394&ltype=S

Major players operating in the global personalized medicine market are Abbott Laboratories, Merck & Co., Inc., AstraZeneca, Pfizer, Inc., GlaxoSmithKline plc., Novartis AG, Amgen, Inc., Bayer AG, Mylan N.V., Eli Lilly and Company, Bristol Myers Squibb Co., Daiichi Sankyo Company, Ltd., Biogen, Inc., Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., Novo Nordisk A/S, and Sanofi Genzyme.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Follow this link:
Personalized Medicine Market: Rise in the Prevalence of Various Types of Cancer to Drive the Global Market - Science Examiner

DUBLIN--(BUSINESS WIRE)--Jun 29, 2020--

The "Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company" report has been added to ResearchAndMarkets.com's offering.

The global digital genome market was valued at US$ 11,065.31 million in 2019 and is projected to reach US$ 20,812.81 million by 2027; it is expected to grow at a CAGR of 8.4% during 2020-2027.

The growth of the digital genome market is mainly attributed to factors such as the increasing prevalence of chronic diseases and growing funding for genomics. However, dearth of skilled professionals is likely to restraint the growth of the market during the forecast years.

Genomic sequencing is rapidly transitioning into clinical practice, and implementation into healthcare systems has been supported by substantial government investment, accounting for US$ 4 billion in at least 14 countries. These national genomic medicine initiatives are driving transformative change under real-life conditions while simultaneously addressing barriers to implement and gather evidence for broader adoption.

The UK has announced the world's largest genome project as part of 200 million public-private collaboration between charities and pharmaceutical. The UK has already developed the largest genome database in the world through the 100,000 Genomes Project. Led by Innovate UK as part of UK Research and Innovation, the project will fund researchers and industry to combine data and real-world evidence from UK health services and create new products and services that diagnose diseases efficiently.

Moreover in August 2018, Nebula Genomics, a Massachusetts-based company announced that it landed US$ 4.3 million in seed funding and that it would be partnering with Veritas Genetics, a genome sequencing company. The funds will support the company's mission to usher in the era of personal genome sequencing by creating a trusted, secure, and decentralized marketplace for genomic data.

Cardiovascular diseases (CVDs) such as atherosclerosis, angina pectoris, and acute myocardial infarction are a significant cause for mortality in the world owing to the present day hectic lifestyle. As per the data provided by WHO, CVDs are the number 1 cause of death globally, taking an estimated 17.9 million lives each year. Diabetes is one of the life-threatening chronic diseases with no functional cure. Diabetes of all types can lead to various complications in different parts of the body and can increase the overall risk of premature death.

Heart attack, stroke, kidney failure, leg amputation, vision loss, and nerve damage are the major complications associated with diabetes. As there is a significant increase in diabetes cases across the world, it results in life-changing complications among the population. According to the International Diabetes Federation (IDF), in 2017, 46 million diabetic patients were reported in North America, which is expected to reach 62 million in 2045. As chronic diseases are increasing at a faster pace, the research on genomics for life-threatening illnesses has progressed rapidly over the last five years, thereby driving the market growth during the forecast period.

Based on product, the digital genome market is segmented into DNA/RNA analysis, sequencing chips, sequencing and analyzer instruments, sample prep instruments, and sequencing and analysis software. The sequencing and analyzer instruments segment held the largest share of the market in 2019; whereas, the sequencing chips segment is estimated to register the highest CAGR in the market during the forecast period.

Based on application, the digital genome market is segmented into diagnostics, agricultural, academic research, drug discovery, personalized medicine, and other applications. The diagnostics segment held the largest share of the market in 2019; however, personalized medicine segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the global digital genome market is segmented into diagnostics and forensic labs, academic research institutes, hospitals, and others. The diagnostics and forensic labs segment held the highest share of the market in 2019; whereas, the academic research institutes segment is estimated to register the highest CAGR in the market during the forecast period.

Key Topics Covered

1. Introduction

1.1 Scope of the Study

1.2 Report Guidance

1.3 Market Segmentation

1.3.1 Global Digital Genome Market - By Product

1.3.2 Global Digital Genome Market - By Application

1.3.3 Global Digital Genome Market - By End-user

1.3.4 Global Digital Genome Market - By Geography

2. Digital Genome Market - Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Global Digital Genome Market - Market Landscape

4.1 PEST Analysis

4.1.1 North America - PEST Analysis

4.1.2 Europe - PEST Analysis

4.1.3 Asia-Pacific - PEST Analysis

4.1.4 Middle East and Africa - PEST Analysis

4.1.5 South and Central America - PEST Analysis

4.2 Expert Opinion

5. Digital Genome Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Growing Funding for Genomics

5.1.2 Increasing Prevalence of Chronic Diseases

5.2 Market Restraints

5.2.1 Dearth of Skilled Professionals

5.3 Market Opportunities

5.3.1 Increasing Technological Advancement in Digital Genome Field

5.4 Future Trends

5.4.1 Increasing Demand for Personalized Medicines

5.5 Impact analysis

6. Digital Genome Market - Global Analysis

6.1 Global Digital Genome Market Revenue Forecast and Analysis

6.2 Global Digital Genome Market, By Geography - Forecast and Analysis

6.3 Market Positioning of Key Players

7. Digital Genome Market Analysis - By Product

7.1 Overview

7.2 Digital Genome Market Revenue Share, by Product (2019 and 2027)

7.3 DNA/RNA Analysis

7.4 Sequencing and Analyzer Instruments

7.5 Sequencing and Analysis Software

7.6 Sequencing Chips

7.7 Sample Prep Instruments

8. Digital Genome Market - By Application

8.1 Overview

8.2 Digital Genome Market, by Application, 2019 and 2027 (%)

8.3 Diagnostics

8.4 Drug Discovery

8.5 Academic Research

8.6 Personalized Medicine

8.7 Agricultural

8.8 Others

9. Digital Genome Market - By End-user

9.1 Overview

9.2 Digital Genome Market, by End-user, 2019 and 2027 (%)

9.3 Diagnostics & Forensic Labs

9.5 Academic Research Institutes

9.6 Hospitals

9.7 Other End-users

10. Digital Genome Market - Geographic Analysis

10.1 North America: Digital Genome Market

10.2 Europe: Digital Genome Market

10.3 Asia-Pacific: Digital Genome Market

10.4 Middle East & Africa: Digital Genome Market

10.5 South and Central America: Digital Genome Market

11. Impact of COVID-19 Pandemic on Global Digital Genome Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Digital Genome Market - Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.4 Inorganic Developments

13. Company Profiles

13.1 Thermo Fisher Scientific Inc.

13.2 F. Hoffmann-La Roche Ltd.

13.3 Illumina, Inc.

13.4 QIAGEN

13.5 GenomeMe

13.6 NanoString Technologies, Inc.

13.7 BD

13.8 bioMerieux SA

13.9 GenMark Diagnostics, Inc.

13.10 Perkin Elmer, Inc.

See the article here:
Global Digital Genome Market Forecast to 2027 - COVID-19 Impact and Analysis by Product, Application, End-user, Geography and Company -...

UTRECHT, Netherlands, June 29, 2020 /PRNewswire/ -- Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targeted Locus Amplification (TLA) technology, today announced the appointment of Joris Schuurmans as CEO and Dirk Pollet and Maja Sanders as Supervisory Board members. Novalis Biotech Incubation will invest in Cergentis' growth potential.

Incoming CEO Joris Schuurmans has extensive experience in the molecular diagnostics and biopharmaceutical industry. He held senior executive positions at Biocartis and MyCartis, and recently lead Skyline Dx' melanoma program prior to transitioning to his role at Cergentis.

Joris Schuurmans commented: "I am very excited by the opportunity to join Cergentis at this pivotal stage. Cergentis has developed an impressive array of products and services in the field of genetic engineering, and is extremely well-positioned to enter the molecular diagnostics field with products that elucidate DNA variants in tumors that cannot be well-analyzed with current technologies. We are all excited to embark on our mission to improve diagnosis and treatment of cancer patients."

Dr. Jan Groen, Chairman of the Board: "A heartfelt gratitude to outgoing CEO Jan Dekker, who laid the foundation for Cergentis to take the next step to accelerate the development and commercialization of its unique TLA technology for cancer diagnostics. We are pleased to welcome Joris as new CEO. Joris has an excellent international track record in the biotech industry. We are also very pleased with the appointment of our new Board members Maja and Dirk."

Dr. Dirk Pollet, industry veteran, heralded the acquisition of Multiplicom by Agilent as CEO of Multiplicom, is currently CEO of Enzyre. Maja Sanders currently holds supervisory roles at various (non-)profit organizations and has built up extensive managerial experience in the private equity industry.

Novalis Biotech Incubation, a venture capital investment fund, is investing in Cergentis.

Wim Van Criekinge, Co-founder of Novalis: "We are pleased to invest in Cergentis. Their technology is unique and allows the most advanced genome characterization to date."

About Cergentis

Cergentis is a genomics company that develops and commercializes TLA-based diagnostic kits for targeted complete next-generation sequencing of (trans)genes and gene editing events. The company also provides commercial services for leading research institutes and pharmaceutical companies worldwide. TLA is a well-established technology thatprovides unique and critical advantages in the implementation of personalized medicine. For more information: cergentis.com.

SOURCE Cergentis

https://www.cergentis.com

Originally posted here:
Cergentis Appoints New CEO and Board Members - PRNewswire

Biopreservationis the process of improving safety of food products and extending their shelf life through utilization of their controlled or natural microflora. Biopreservation process makes the use of lactic acid bacteria (LAB) as the main tool and they are mainly considered as generally recognized as safe (GRAS) products. The global biopreservation market is estimated to witness substantial growth over the tenure of assessment owing to the high prevalence of various chronic diseases. Lactic acid bacteria can restrict the growth of the various microorganisms, which comprises fungi, yeasts, and bacteria.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1340

Increased prevalence of various chronic diseases such as obesity, diabetes, renal diseases, and cardiac illnesses is likely to work in favor of the global biopreservation market in the years to come. According to the National Diabetes Statistics Report 2020, around 34.2 million people in the US, which is just over 1 in 10 and 10.5 % of the US population, suffer from diabetes. In addition, dearth of organ donors for the purpose of transplantation is likely to augment the demand for regenerative medicines. This factor is likely to boost the global biopreservation market over the tenure of assessment.

Growing investment in research and development in drug discovery is likely to impact the growth of the global biopreservation market in the near future. Rise in the number of bio-banks for storing various biological products utilized in medical research is likely to augur well for the rapid expansion of the market. Furthermore, as coronavirus spreads across the globe killing thousands, the demand for medical research to find a solution to contain the disease is on the rise. As such, the demand for biopreservation is expected to swell riding on the back of spread of coronavirus across the globe.

Increased Spending on Research and Development Activities to Bolster Demand

In the global biopreservation market, biobanking is estimated to experience considerable growth over the timeframe of analysis. Biobanks refer to the biorepositories that preserve and store various biological samples utilized in medical research. Rising demand for biospecimens for supporting contemporary researches in genomics and personalized medicine is likely to escalate the adoption of biobanking. With the rise in biobanking, the demand for biopreservation is predicted to rise in the near future.

Regenerative medicines in the global biopreservation market are likely witness lucrative growth over the analysis timeframe. Rising adoption of regenerative medicines for treating severe to life-threatening conditions is likely to foster growth of the regenerative medicines. Increased prevalence of chronic diseases has often led to various organ deformities, which has generated demand for organ transplantation. Regenerative medicines comprise regeneration or engineering of human tissues, organs or cells to establish or restore normal functioning of organs. Dearth of organ donors is also expected to drive the demand for regenerative medicines in the years to come.

On the other hand, stringent regulations pertaining to the production of biopreservation items is likely to hamper the growth of the global biopreservation market. Furthermore, emergence of storage techniques that could store such products at room temperature is further likely to limit growth of the market in the near future.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1340

Driven by Rising Incidences of Lifestyle Diseases, US to Lead the Market

U.S. biopreservation market is predicted to account for a sizeable chunk of the market and is expected to experience substantial growth over the period of assessment. Rising prevalence of various lifestyle diseases such as renal diseases, obesity, and diabetes often leads to organ damages, which is likely to offer lucrative growth opportunities for the biopreservation market in the US.

The UK is another promising region for the global biopreservation market and the region is estimated to continue with the similar trend over the years of assessment. Such growth of the country is ascribed to the augmented support from the government for smooth functioning of the biobanks. The government also assists in the networking of biobanks such as UK biobank and international collaborations for the expansion of the scope of biobanking. This factor is likely to bolster the growth of the biopreservation market in the region.

Presence of Several Market Players to Bolster Demand in the Market

Some of the prominent industry players found in the global biopreservation market compriseBioLife Solutions, Inc., Thermo Fisher Scientific Inc., Atlanta Biologicals Inc., Custom Biogenic Systems, Panasonic Biomedical, and Taylor-Wharton International LLC.The global biopreservation market is regarded as a fragmented one owing to the presence of several market players. Furthermore, the market is likely to be characterized by acquisitions, mergers, and product launches.

Avail the Discount on this Report @https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1340

Original post:
Biopreservation Market Latest Trends and Analysis Future Growth Study by 2025 - Cole of Duty

GE Healthcare Enterprise Tech Ecosystem Series

Summary

GE Healthcare is tapping the power of 3D printing, genomics, mobile health, artificial intelligence, cloud, big data, remote patient monitoring, IoT, and precision & personalized medicine to offer connected care and improve workflow.

The company provides mentorship and investment support to startups through its in-house accelerator programs, such as Five.eight and Edision[X], and cco-develop solutions through own and partner innovation centers.

Grab a Free sample copy of the report from here:https://www.researchmoz.us/enquiry.php?type=S&repid=2706993

GE Healthcare acquired tech companies, namely, Monica Healthcare and Zenith Technologies.

The companys venture investment arm is called GE Ventures (GEV), which invest in both healthcare and non-healthcare sectors. The investments are made in Nuvolo Technologies, Vineti, and Genome Medical to name a few.

The report provides information and insights into GE Healthcares tech activities, including Insights of its digital transformation strategies, innovation centers, and accelerator programs Overview of technology initiatives covering partnerships and innovative product and solution launch Insights on each technology initiative including technology theme, objective, and benefits Details of estimated ICT budgets and major ICT contracts

Scope

GE Healthcare created a remotely managed private cloud-as-a-service dubbed GE Infrastructure Xchange (GEIX) powered by OpenStack and run through Rackspace for hosting all its applications. The company focuses on developing software-based digital solutions that use technologies like predictive, preventive, and perspective analytics to provide caregivers with increased access to data, analytics, connectivity, and insights on operational processes and workflows. In 2019, GE Healthcare partnered with NASSCOM CoE-IoT, an innovation hub based in India. In 2019, the company launched its first start-up collaboration program known as Edison[X].

Browse complete report description And Full TOC @https://www.researchmoz.us/enquiry.php?type=E&repid=2706993

Reasons to Buy

Gain insights into GE Healthcares tech operations. Gain insights into its tech strategies, innovation centers, and accelerator initiatives. Gain insights into its technology themes under focus. Gain insights into various technology introduction, adoption, and partnership strategies of GE Healthcare.

For More Information Kindly Contact:ResearchMozMr. Rohit Bhisey,90 State Street,Albany NY,United States 12207Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]Media Release @https://www.researchmoz.us/pressreleaseFollow me on Blogger:https://trendingrelease.blogspot.com/

Link:
Addressing the potential impact of coronavirus disease (COVID-19) on GE Healthcare-Enterprise Tech Ecosystem Series Market: Quantitative Analysis from...

Lab-on-chipsis an integrated miniaturized device used in the laboratory operations on a single micro-process chip in small scale. Lab-on-chip is also called as micro-total analytical system. Complex tests can be performed on a single chip by combining microfluidics and microelectronics using Lab-on-chips. Lab-on-chip has its main application in biotechnological and medical applications such as medical diagnostics, chemical synthesis and the study of complex cellular process, thus providing quick diagnosis.

Lab Chip devices are influencing the Laboratory Testing market where trace samples are to be analysed in the field if medical examination. Being handy, portable, and easy to use these devices are extensively used in hospitals and various surgical centres as well, thus promising the growth of global Lab Chip Devices Market in the near future.

Get Access to sample pages @ https://www.trendsmarketresearch.com/report/sample/3299

Diagnostics will hold the largest segment globally, because of the growing demand for diagnostics with high speed, efficiency, and sensitivity of results with accuracy. Diagnostics segment is expected to expand at the highest CAGR of 11.3% over the period from 2018 to 2026. Day by day increasing global population is continuously increasing the number of patients with diseases and thus the demand for microfluidic systems for diagnosis, treatment, and monitoring of these diseases. The Lab on chips contributes to the rise in personalized medicine, drug discovery and life science research, and growing need for high speed diagnostics. These factors will lead the diagnostics segment across different regions of the world.

North America has the highest revenue share in 2017 due to more demand for microfluidic products in the pharma, diagnostic, and clinical sectors for its cost-effectiveness and multi functionality. In North America, market players are developing advanced microfluidic products continuously. The U.K. holds highest share in Europe market with a significant growth. Whereas in APAC, the demand is mainly concentrated in China and India, due to the increasing population and popularity of conventional biological laboratories.

Some of the key players in the global lab-on-chips application market are EMD Millipore, Life Technologies Corporation, Abbott Laboratories, Roche Diagnostics, Siemens Healthcare, Bio-Rad Laboratories.

Based on application:

Clinical Diagnostics

Genomics

In vitro Diagnostics

Point of Care Diagnostics

Proteomics

Drug Discovery

Others (Biodefense, Food Pathogen Identification, and Environmental Contamination)

Based on the end user type:

Biotechnology and Pharmaceutical Companies

Hospitals

Forensic Laboratories

Diagnostics Centers

Academic & Research Institutes

Go here to read the rest:
Lab-On-Chips Market: Opportunities and Forecast Assessment, 2018 to 2025 - Cole of Duty

Proteomics refers to the field of study of the expression of genetic information at the protein level (proteome). Mass spectrometry (MS) is one of the high-growth areas in automation in proteomics. Automation feature includes temperature control, reagent handling and integrated robotics and a bar code reader to handle many samples at a point of time. Automation is a leading feature in this market as profits are based on the number of samples hence high throughput is very important and this can be easily achieved through automation.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10064997

Market DynamicsThe rapidly growing demand for personalized medicine, R&D expenditure, technological advancements, and increased funding for proteomics projects are prime drivers for automation in the proteomics market. Moreover, need for consistency in quality and a high cost of error also act as growth drivers.Lack of planning for technology development, low priority for lab automation among small and medium-sized laboratories and high initial setup cost put constraints on the market.

Market SegmentationThe globallab automation marketis segmented by equipment and software (automated liquid handling, microplate readers, standalone robots, software and informatics, ASRS), by applications (clinical diagnostics, drug discovery, genomics solutions, proteomics solutions), by type of automation (modular automation and total lab automation), by end users (biotech and pharma, hospitals and private labs, academics and research institutes).

Geographic AnalysisNorth America and Europe lead the global lab automation in proteomics market along with Canada and Japan. Asia Pacific and Latin American countries represent emerging markets.

Request For Full Report:https://www.kennethresearch.com/sample-request-10064997

Key PlayersSome of the major players in the market includeGilent Technologies Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, GE Healthcare, Luminex Corporation, Merck, PerkinElmer Inc., Thermo Fisher Scientific, Inc. and Waters Corporation.

About UsKenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation.

Contact UsKenneth ResearchEmail:[emailprotected]Phone:+1 313 462 0609

Read more:
Lab Automation in Proteomics Market By Brand and major players 2020-2022 - 3rd Watch News

The market research report published by QYResearch is a brilliant, in-depth, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Nucleic Acid Amplification Testing market. It informs readers about key trends and opportunities in the global Nucleic Acid Amplification Testing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Nucleic Acid Amplification Testing market.

Key companies operating in the global Nucleic Acid Amplification Testing market include , F. Hoffmann-La Roche, Becton, Dickinson and Company, Beckman Coulter, Abbott Laboratories, Illumina, Siemens Healthineers, bioMerieux, Novartis, Bio-Rad Laboratories Nucleic Acid Amplification Testing

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1528651/global-nucleic-acid-amplification-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Nucleic Acid Amplification Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Nucleic Acid Amplification Testing Market Segment By Type:

, Target Amplification Systems, Probe Amplification Systems, Signal Amplification Nucleic Acid Amplification Testing

Global Nucleic Acid Amplification Testing Market Segment By Application:

, Infectious Diseases, Cancer, Personalized Medicine, Genetic and Mitochondrial Disorders

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Nucleic Acid Amplification Testing market.

Key companies operating in the global Nucleic Acid Amplification Testing market include , F. Hoffmann-La Roche, Becton, Dickinson and Company, Beckman Coulter, Abbott Laboratories, Illumina, Siemens Healthineers, bioMerieux, Novartis, Bio-Rad Laboratories Nucleic Acid Amplification Testing

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1528651/global-nucleic-acid-amplification-testing-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Nucleic Acid Amplification Testing Revenue1.4 Market Analysis by Type1.4.1 Global Nucleic Acid Amplification Testing Market Size Growth Rate by Type: 2020 VS 20261.4.2 Target Amplification Systems1.4.3 Probe Amplification Systems1.4.4 Signal Amplification1.5 Market by Application1.5.1 Global Nucleic Acid Amplification Testing Market Share by Application: 2020 VS 20261.5.2 Infectious Diseases1.5.3 Cancer1.5.4 Personalized Medicine1.5.5 Genetic and Mitochondrial Disorders1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends by Regions2.1 Nucleic Acid Amplification Testing Market Perspective (2015-2026)2.2 Nucleic Acid Amplification Testing Growth Trends by Regions2.2.1 Nucleic Acid Amplification Testing Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Nucleic Acid Amplification Testing Historic Market Share by Regions (2015-2020)2.2.3 Nucleic Acid Amplification Testing Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Nucleic Acid Amplification Testing Market Growth Strategy2.3.6 Primary Interviews with Key Nucleic Acid Amplification Testing Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Nucleic Acid Amplification Testing Players by Market Size3.1.1 Global Top Nucleic Acid Amplification Testing Players by Revenue (2015-2020)3.1.2 Global Nucleic Acid Amplification Testing Revenue Market Share by Players (2015-2020)3.1.3 Global Nucleic Acid Amplification Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Nucleic Acid Amplification Testing Market Concentration Ratio3.2.1 Global Nucleic Acid Amplification Testing Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Nucleic Acid Amplification Testing Revenue in 20193.3 Nucleic Acid Amplification Testing Key Players Head office and Area Served3.4 Key Players Nucleic Acid Amplification Testing Product Solution and Service3.5 Date of Enter into Nucleic Acid Amplification Testing Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Nucleic Acid Amplification Testing Historic Market Size by Type (2015-2020)4.2 Global Nucleic Acid Amplification Testing Forecasted Market Size by Type (2021-2026) 5 Nucleic Acid Amplification Testing Breakdown Data by Application (2015-2026)5.1 Global Nucleic Acid Amplification Testing Market Size by Application (2015-2020)5.2 Global Nucleic Acid Amplification Testing Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Nucleic Acid Amplification Testing Market Size (2015-2020)6.2 Nucleic Acid Amplification Testing Key Players in North America (2019-2020)6.3 North America Nucleic Acid Amplification Testing Market Size by Type (2015-2020)6.4 North America Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 7 Europe7.1 Europe Nucleic Acid Amplification Testing Market Size (2015-2020)7.2 Nucleic Acid Amplification Testing Key Players in Europe (2019-2020)7.3 Europe Nucleic Acid Amplification Testing Market Size by Type (2015-2020)7.4 Europe Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 8 China8.1 China Nucleic Acid Amplification Testing Market Size (2015-2020)8.2 Nucleic Acid Amplification Testing Key Players in China (2019-2020)8.3 China Nucleic Acid Amplification Testing Market Size by Type (2015-2020)8.4 China Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 9 Japan9.1 Japan Nucleic Acid Amplification Testing Market Size (2015-2020)9.2 Nucleic Acid Amplification Testing Key Players in Japan (2019-2020)9.3 Japan Nucleic Acid Amplification Testing Market Size by Type (2015-2020)9.4 Japan Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Nucleic Acid Amplification Testing Market Size (2015-2020)10.2 Nucleic Acid Amplification Testing Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Nucleic Acid Amplification Testing Market Size by Type (2015-2020)10.4 Southeast Asia Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 11 India11.1 India Nucleic Acid Amplification Testing Market Size (2015-2020)11.2 Nucleic Acid Amplification Testing Key Players in India (2019-2020)11.3 India Nucleic Acid Amplification Testing Market Size by Type (2015-2020)11.4 India Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Nucleic Acid Amplification Testing Market Size (2015-2020)12.2 Nucleic Acid Amplification Testing Key Players in Central & South America (2019-2020)12.3 Central & South America Nucleic Acid Amplification Testing Market Size by Type (2015-2020)12.4 Central & South America Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 13 Key Players Profiles13.1 F. Hoffmann-La Roche13.1.1 F. Hoffmann-La Roche Company Details13.1.2 F. Hoffmann-La Roche Business Overview and Its Total Revenue13.1.3 F. Hoffmann-La Roche Nucleic Acid Amplification Testing Introduction13.1.4 F. Hoffmann-La Roche Revenue in Nucleic Acid Amplification Testing Business (2015-2020))13.1.5 F. Hoffmann-La Roche Recent Development13.2 Becton13.2.1 Becton Company Details13.2.2 Becton Business Overview and Its Total Revenue13.2.3 Becton Nucleic Acid Amplification Testing Introduction13.2.4 Becton Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.2.5 Becton Recent Development13.3 Dickinson and Company13.3.1 Dickinson and Company Company Details13.3.2 Dickinson and Company Business Overview and Its Total Revenue13.3.3 Dickinson and Company Nucleic Acid Amplification Testing Introduction13.3.4 Dickinson and Company Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.3.5 Dickinson and Company Recent Development13.4 Beckman Coulter13.4.1 Beckman Coulter Company Details13.4.2 Beckman Coulter Business Overview and Its Total Revenue13.4.3 Beckman Coulter Nucleic Acid Amplification Testing Introduction13.4.4 Beckman Coulter Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.4.5 Beckman Coulter Recent Development13.5 Abbott Laboratories13.5.1 Abbott Laboratories Company Details13.5.2 Abbott Laboratories Business Overview and Its Total Revenue13.5.3 Abbott Laboratories Nucleic Acid Amplification Testing Introduction13.5.4 Abbott Laboratories Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.5.5 Abbott Laboratories Recent Development13.6 Illumina13.6.1 Illumina Company Details13.6.2 Illumina Business Overview and Its Total Revenue13.6.3 Illumina Nucleic Acid Amplification Testing Introduction13.6.4 Illumina Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.6.5 Illumina Recent Development13.7 Siemens Healthineers13.7.1 Siemens Healthineers Company Details13.7.2 Siemens Healthineers Business Overview and Its Total Revenue13.7.3 Siemens Healthineers Nucleic Acid Amplification Testing Introduction13.7.4 Siemens Healthineers Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.7.5 Siemens Healthineers Recent Development13.8 bioMerieux13.8.1 bioMerieux Company Details13.8.2 bioMerieux Business Overview and Its Total Revenue13.8.3 bioMerieux Nucleic Acid Amplification Testing Introduction13.8.4 bioMerieux Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.8.5 bioMerieux Recent Development13.9 Novartis13.9.1 Novartis Company Details13.9.2 Novartis Business Overview and Its Total Revenue13.9.3 Novartis Nucleic Acid Amplification Testing Introduction13.9.4 Novartis Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.9.5 Novartis Recent Development13.10 Bio-Rad Laboratories13.10.1 Bio-Rad Laboratories Company Details13.10.2 Bio-Rad Laboratories Business Overview and Its Total Revenue13.10.3 Bio-Rad Laboratories Nucleic Acid Amplification Testing Introduction13.10.4 Bio-Rad Laboratories Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.10.5 Bio-Rad Laboratories Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the article here:
Nucleic Acid Amplification Testing Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026| F....

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Artificial Intelligence in Healthcare market.

Trusted Business Insights presents an updated and Latest Study on Artificial Intelligence in Healthcare Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Artificial Intelligence in Healthcare market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Artificial Intelligence in Healthcare Market, Market Research and Industry Forecast Report, 2019-2025 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Artificial Intelligence in Healthcare Market

The global artificial intelligence in healthcare market size was valued at USD 2.5 billion in 2018 and is anticipated to grow at a CAGR of 41.5% over the forecast period. The growing need for lowering healthcare costs, growing importance of big data in healthcare, rising adoption of precision medicine, and declining hardware costs are some factors driving growth. In addition, increasing applicability of AI-based tools in medical care and rise in venture capital investments can be attributed to the surge in demand for this technology. For instance, CarePredict, Inc. uses AI technology to monitor changes in behavior patterns and activity for early detection of health issues.Increasing number of cross-industry partnerships is expected to boost adoption of AI in the healthcare sector, which is further responsible for its lucrative growth rate. In September 2018, GNS Healthcare entered into a cross-industry partnership with Alliance and Amgen for clinical trials in oncology. The collaboration was aimed at applying data from clinical trials and Artificial Intelligence (AI) to identify factors that expedite treatment responses in metastatic Colorectal Cancer (CRC) patients. Likewise, Microsoft announced partnership with Apollo Hospitals, one of the prominent healthcare systems in India, in March 2018. The partnership is focused on developing and deploying new machine learning models for predicting the risk of developing cardiac diseases and aid doctors in treatment planning.

Number of artificial intelligence start-ups in healthcare sector has significantly grown in past few years, and the trend is expected to be the same in the coming years, which will in turn, will positively impact the market. Rise in venture capital funding in this domain is a key factor accountable for increase in the number of these start-ups. For instance, in July 2018, Kleiner Perkins and GV invested USD 21 million in Viz.ai-an AI in healthcare start-up. Similarly, HealthPlix Technologies Pvt. Ltd. raised USD 3 million in a Series A funding round led by Kalaari capital and IDG Ventures India in July 2018. Some of the prominent venture capitalist firms operating in this sector are ACCEL PARTNERS, Data Collective, General Catalyst Partners, Khosla Ventures, and others.Adoption of AI in healthcare is growing, with rise in focus on improving quality of patient care by utilizing artificial intelligence in various aspects of healthcare services, such as virtual assistants & surgeries. The AI-based tools, such as clinical decision support systems & voice recognition software, aid in streamlining workflow processes in hospitals and improving medical care, thereby enhancing patient experience.Moreover, shortage of physicians in some countries is anticipated to increase the demand for AI technology. Few companies are engaged in developing such virtual assistants. For instance, in September 2017, Nuance Communications unveiled an AI-based virtual assistance designed specifically for healthcare providers and patients. The incorporation of AI in healthcare has various benefits for both patients as well as healthcare providers. For instance, AI enables personalized care, based on health condition and past medical history. Moreover, AI-based apps can be used for continuous monitoring of health, which would in turn ensure timely care & treatment and can eventually reduce hospital stay.

Component Insights of Artificial Intelligence in Healthcare Market

Software solutions segment held the largest share in the artificial intelligence in healthcare market in 2018. The development of AI-based software solutions for healthcare is one of the key factors boosting segment growth. For instance, Nuance Communications develops a software named Dragon Medical One. According to Nuance Communications, this software can help healthcare companies as well as providers transcribe a physicians speech into an Electronic Health Record (EHR) via natural language processing. Companies such as Google, IBM, and Microsoft are develop and offer machine learning framework.Hardware segment is expected to grow with a CAGR 40.0% over the forecast period. The growing need for hardware platforms with high computing power to operate several AI-based software is one of the major factors contributing to segment growth. Processers such as ASICs, MPUs, GPUs, and FPGAs are used in AI-based platforms designed for use in healthcare.The growth of services segment can majorly be attributed to the rising need for integration and deployment of AI solutions. Moreover, the rise in adoption of AI platforms in the healthcare sector has increased the need for maintenance and support services, which are imperative to keep the devices functional.

Application Insights of Artificial Intelligence in Healthcare Market

Clinical trials emerged as the largest segment in terms of application and was valued at USD 620.5 million in 2018. Unsuccessful clinical trials generally lead to delay/failure of launch of drug candidates in the market. In order to automate clinical trial processes, pharmaceutical companies are focusing on integrating them with artificial intelligence. According to an analysis published by Accenture, the annual value for clinical trial participant identifier is estimated to reach USD 13 billion by 2026 on using this technology.

The adoption of artificial intelligence in robotic-assisted surgery platforms is anticipated to grow at significant pace and the segment is expected to show a lucrative CAGR over the forecast period. Such robots can integrate information from actual surgical experiences to form new improved insights. Such improvement is expected to enhance overall surgical outcome, thereby, enhancing consumer trust on AI integration across surgery centers. Virtual assistant is another lucrative healthcare application of AI technology. AI-enabled virtual assistant can lower the number of physician visits required by a patient, as it can assist by remotely monitoring a patients symptoms and delivering alerts to the respective healthcare professional. In addition, these virtual assistants can save about 20% of the time a nurse by omitting unnecessary visits.Regional InsightIn 2018, North America dominated the global market. Rising adoption of healthcare IT solutions, well-established healthcare sector, and availability of funding for developing AI capabilities are some of the factors contributing to the growth of the market in the region. The U.S. held the largest revenue share in North America, and is anticipated to maintain its position over the forecast period. Advancements in technology and several government initiatives are aiding adoption of digital platforms in life sciences, which can also be attributed to this share.Asia Pacific is expected to emerge as the fastest growing region. Improving infrastructure for healthcare IT, rising number of AI start-ups, and gradually increasing adoption of advanced technologies are some of the factors contributing to market growth. Rise in number of government initiatives for AI technology in this region is also expected to support growth. For instance, in March 2019, in South Korea, the Ministry of Science and ICT announced that it would initiate a trial service of an AI-based precision medicine service named Dr. Answer, in December 2019.

Market Share Insights of Artificial Intelligence in Healthcare Market

IBM Corporation; NVIDIA Corporation; Nuance Communications, Inc.; Microsoft; Intel Corporation; and DeepMind Technologies Limited are among the major players. Investments in R&D, collaborations with other industry participants, and service differentiation are among the key strategies adopted by these players for gaining a competitive edge. For instance, in February 2019, IBM Corporation announced a 10-year partnerships, including an investment of USD 50 million in AI research, with Vanderbilt University Medical Center and Brigham and Womens Hospital.

p2 Segments covered in the reportThis report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, this market research report has segmented global artificial intelligence in healthcare market report on the basis of component, application, and region:

Component Outlook (Revenue, USD Million, 2019 2030)

Software Solutions

Hardware

Services

Application Outlook (Revenue, USD Million, 2019 2030)

Robot-assisted Surgery

Virtual Assistants

Administrative Workflow Assistants

Connected Machines

Diagnosis

Clinical Trials

Fraud Detection

Cybersecurity

Dosage Error Reduction

Quick Read Table of Contents of this Report @ Artificial Intelligence in Healthcare Market, Market Research and Industry Forecast Report, 2019-2025 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Originally posted here:
Artificial Intelligence in Healthcare MARKET REPORT 2020 TO 2028 MARKET ANALYSIS, SIZE, SHARE, TRENDS, KEY PLAYERS, DRIVERS AND FORECAST - Cole of...

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Clinical Oncology Next Generation Sequencing market.

Trusted Business Insights presents an updated and Latest Study on Clinical Oncology Next Generation Sequencing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Clinical Oncology Next Generation Sequencing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Clinical Oncology Next Generation Sequencing Market Size Report 2025 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Clinical Oncology Next Generation Sequencing Market

The global clinical oncology next generation sequencing market size was estimated at USD 627.2 million in 2018. Significant increase in the adoption of genome-focused pharmacology for cancer treatment is expected to provide growth avenues for the market. NGS serves as one of the highly advanced genomic techniques for the analysis of mutations that lead to cancer progression.The growth of the market is supplemented by decrease in the cost of genetic sequencing, advancements in the field of personalized medicine and oncology, rise in prevalence of cancer, globally, and increase in adoption of this technique over single-gene testing. Since this technique is more reliable than Sanger sequencing for diagnosis, the market is expected to witness substantial growth over the forecast period.

Breakthrough advancements in the development of genetic-based tests for oncology and other disorders during the past few years have significantly propelled market growth. Next generation sequencing technology offers a better understanding of tumor mechanism, thus enabling rational drug design. As a result, more products are expected to get commercialized in the near future.A rise in oncology-related spending is further expected to fuel market growth in the coming years. Government organizations are focused on encouraging patients to regularly undergo diagnostic examinations to reduce oncology-related healthcare expenditures. As per data estimates, healthcare expenditure is anticipated to rise significantly, thereby influencing the adoption of NGS diagnostics platforms.The biotechnology industry is marked by high competition and so is the NGS market for clinical as well as research applications. Prominent participants are actively involved in R&D to develop novel rapid, small, and less expensive platforms. Service providers are embracing the trend of increasing the amount of constructed sequence reads for each cycle run.Commercially available sequencing platforms analyze both DNA and RNA samples. Key players aim to increase the utility of high throughput technologies for clinical applications. The acquisition of smaller entities operating in the market is also one of the strategic initiatives adopted by players to maintain a competitive position. For instance, in May 2018, Illumina acquired Edico Genome to accelerate data analysis for its next generation sequencing platforms.

Technology Insights of Clinical Oncology Next Generation Sequencing Market

Targeted sequencing in clinical oncology accounted for the largest revenue share in 2018 and is expected to maintain its share over the forecast period. Targeted sequencing and resequencing encompasses shortest read lengths and is one of the conventional forms of commercially available sequencing technology. Moreover, focused panels for targeted cancer sequencing aid in the reduction of cost burdens owing to reduction in the amount of data to be analyzed. As targeted cancer sequencing evaluates a limited gene-set, it can be used to analyze variations in rare tumor sub-clones with greater sensitivity and deep coverage.The whole-genome sequencing segment is expected to grow at the fastest rate through 2025. Application of whole genome sequencing technology for comparisons between tumor tissue and normal tissue in clinical oncology is attributive to segment growth. Developed rapid, large-capacity sequencers such as HiSeq and MiSeq series find application in largescale whole genome sequencing.Workflow InsightsNGS workflow includes library preparation, sample enrichment, sample quality assurance, DNA tagging, sequencing, DNA quantification, genetic data assemble, data storage and analysis, and interpretation. Sequencing accounted for the largest share in the clinical oncology NGS market as it is the most important and crucial step in the entire process and involves the usage of sophisticated platforms. Continuous R&D has led to the introduction of novel, benchtop, or portable NGS sequencing platforms, thereby complimenting market growth. Moreover, NGS platforms are expected to witness lucrative growth throughout the forecast period owing to the expected increase in adoption and usage rates of whole-genome sequencing.

Application Insights of Clinical Oncology Next Generation Sequencing Market

Next generation sequencing finds application in the field of clinical oncology for screening, companion diagnostics, and others. The adoption of NGS-based molecular diagnosis for oncology has increased as this technology allows concurrent sequencing of several target genes and provides rich diagnostic markers for the development of molecular diagnostic assays.Application of NGS technology in the field of oncology ensures early diagnosis so that treatment measures can be taken in time. Therefore, the arrival of NGS for cancer diagnosis has opened many new frontiers in the field. For instance, large-scale projects such as International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) have issued data from thousands of tumors across major cancer types. This data can be used to have a comprehensive overview of cancerous cells and help enhance prognostic and therapeutic applications.The market for companion diagnostics is expected to grow significantly in the coming years owing to numerous benefits offered by the technique in the field of oncology. Currently, available companion diagnostic products are applicable for non-small cell lung cancer, melanoma, colorectal, ovarian, and breast cancers.End-use InsightsBy way of end use, the clinical oncology next generation sequencingmarket has been segmented into hospitals, clinics, and laboratories. Laboratories held a prominent share in the market for clinical oncology NGS and this trend is likely to continue over the forecast period. The hospitals segment is expected to register a significant CAGR through 2025. Rise in adoption of NGS services in hospitals to determine the rate of disease progression and scale-up the appropriate treatment regimen for cancer is anticipated to influence growth in this segment.

Provision of clinical services by leading players in the market such as Illumina, which includes CLIA certified tests for predisposition screening, is anticipated to boost revenue in the coming years. Clinics utilize NGS technology to identify novel cancer mutations, for genetic testing for hereditary cancer syndrome, for personalized oncology treatment, and for detection of circulating DNA for cancer.

Regional Insights of Clinical Oncology Next Generation Sequencing Market

North America occupied the largest share in the global market in 2018 owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate healthcare infrastructure. Moreover, high prevalence of cancer, growing demand for personalized medicine, well-developed healthcare facilities, and availability of novel diagnostics techniques, especially in the field of oncology, can be attributed to the estimated market share of the region. Additionally, growing morbidity and mortality due to cancer has increased the need for development of novel therapies, thereby driving this regional market.Asia Pacific is expected to be the fastest-growing region throughout the forecast period majorly due to continuous reforms in the healthcare and pharmaceutical industries in the region. Other factors contributing to this growth are untapped markets in emerging economies. The market is continuously driven by rise in cancer incidence across Asia Pacific. China dominates the cancer burden in the region, followed by India, Japan, Indonesia, and the Republic of Korea. The top three types of cancer with his incidences in the region are breast, lung, and prostate cancer.

Market Share Insights of Clinical Oncology Next Generation Sequencing Market

The global market is marked by the presence of high competition among market players. Illumina and Roche account for a substantial share owing to wide product offerings in the field of next-generation sequencing for cancer. Other prominent players operating in this market space include Agilent; Thermo Fisher Scientific; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer, Inc.; Qiagen NV; Partek, Inc.; Pacific Bioscience, Inc.; Foundation Medicine; Oxford Nanopore Technologies Ltd.; Paradigm Diagnostics, Inc.; Caris Life Sciences; and Eurofins Scientific.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Clinical Oncology Next Generation Sequencing Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, this market research report has segmented the globalclinical oncology next generation sequencing market report on the basis of technology, workflow, application, end use, and region:

Technology Outlook (Revenue, USD Million, 2019 2030)

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing

Workflow Outlook (Revenue, USD Million, 2019 2030)

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

Application Outlook (Revenue, USD Million, 2019 2030)

Screening

Sporadic Cancer

Inherited Cancer

Companion Diagnostics

Others

End-use Outlook (Revenue, USD Million, 2019 2030)

Hospitals

Clinics

Laboratories

Quick Read Table of Contents of this Report @ Clinical Oncology Next Generation Sequencing Market Size Report 2025 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Originally posted here:
How COVID-19 Pandemic Will Impact Clinical Oncology Next Generation Sequencing Market Business Opportunity, And Growth 2020-2026 - Cole of Duty

Diabetes has assumed epidemic proportions today and millions of people suffer from this condition globally. There may be many causes behind this problem like family history, unhealthy diet and a sedentary lifestyle. Some environmental pollutants may also trigger this condition. It often brings with it many complications like blurry vision, weight loss and excessive thirst. Uncontrolled blood sugar levels over time can result in serious health issues like kidney problems and diabetic retinopathy. Also Read - Diabetes increases your risk of cancer: Experts blame DNA damage

If you have diabetes, you need to take good care of your feet. This is because one of the complications of this condition is diabetic neuropathy. It leads to loss of sensation in your feet and you may be unaware if you have any injury. This happens because fluctuation in blood sugar levels may damage the nerves and vessels of the feet. Unattended injuries can cause gangrene and it may result in loss of a limb. In fact, diabetic neuropathy is the leading cause of amputations in people with diabetes. Also Read - Know how to deal with wounds if you have diabetes

This complication of diabetes may develop over time and you may not notice it immediately. Some people experience a feeling of thickness on their soles. At times, you may also develop open sores and calluses on your soles. If you have an injury, it will take a longer time to heal. A burning sensation on the feet and extreme sensitivity may also be symptoms of diabetic neuropathy. Also Read - Diabetes alert: Beware of dementia and cancer if you have elevated blood sugar levels

If you have this condition, you must be extra careful when it comes to your feet. If you notice any changes in the shape of your feet or any injury that is not healing, seek immediate medical help. This will help you save your feet. One important thing that you need to do is wear the right shoes. There are now many shoes that are especially designed for people with diabetes. These special shoes are deeper than normal shoes. Choose something that is comfortable and fits you well. Make sure that you can wriggle your toes around after wearing your shoes. Avoid wearing heels and fancy open-toed ones. Straps are bad too as it may sometimes cut into your skin and injure you.

Tip: Shop for footwear at the end of the day when your feet may be slightly swollen. This will help you pick a pair that will not be tight around this time of the day.

You can also ask your doctor about wearing compression socks to stimulate circulation in your lower limbs. Other than this, be gentle with your feet and treat them with love and care. Every night before going to bed, make it a point to check your feet properly for any sings of injury. If you notice anything different, get an appointment with your doctor. Be sure to keep your nails trimmed and groomed. You may also give yourself a regular pedicure and use scrubs to exfoliate your feet at frequent intervals. Be sure to wash your feet with warm water before going to bed every night. This night time ritual will go a long way in keeping your feet safe.

Published : June 29, 2020 7:08 pm

Visit link:
Save your feet from diabetic neuropathy: A few tips to keep your feet healthy - TheHealthSite

Systemic lupus erythematosus (SLE) may have an early effect on peripheral nerve function before the development of electrophysiologic or clinical neuropathy, according to study results published in Rheumatology International.

Researchers evaluated data from nerve conduction studies (NCS) in patients with SLE without clinical or electrophysiologic neuropathy and healthy control participants matched by age and sex. Data included sensory nerve action potential (SNAP), sensory nerve conduction velocities, (SNCV), and demographics. Investigators aimed to determine whether SLE could have an even earlier effect on peripheral nerve function before the development of electrophysiologic abnormalities.

A total of 61 patients with SLE without electrophysiologic neuropathy (88.5% women; median disease duration, 8 years) were included in the study. Patients had a median SLE Disease Activity Index (SLEDAI) score of 3 (range, 0-16). A total of 49.2% of patients had mild disease activity (score, 1-5), and 32.8% showed no active disease (score, 0).

Although NCS results were within the normal range, the researchers found statistically significant differences in several motor and sensory parameters between the patient and control group. Compared with control participants, among patients with SLE, distal compound muscle action potential was significantly lower in the ulnar, fibular, and posterior tibial nerves and motor nerve conduction velocities were significantly slower in the median, ulnar, and fibular nerves. In the sensory NCS, patients with SLE vs control participants showed significantly lower SNAP amplitudes in the sural nerves and slower SNCV in the median, ulnar, and sural nerves. Patients with SLE also had longer minimum F-wave latencies and their H reflexes more frequently absent.

No significant correlations were found between NCS parameters and SLEDAI or disease duration among patients with SLE; however, there were correlations between disease relapses and motor conduction velocities, specifically of the tibial and fibular nerves (r=-0.315; P =.013 and r=-0.426; P =.001).

Researchers noted that NCS measure the function of only large nerve fibers, which may represent a limitation of the study, because small peripheral nerve fibers have also been recognized to be involved in SLE.

Overall, despite having NCS results within a normal range, the data show that patients with SLE without other known causes of neuropathy experienced worse peripheral nerve function. This could suggest that SLE has early negative effects on peripheral nerve function, which supports the possibility that SLE polyneuropathy may gradually progress to development of clinical peripheral neuropathy.

Reference

Fong S-Y, Raja J, Wong K-T, Goh K-J. Systemic lupus erythematosus may have an early effect on peripheral nerve function in patients without clinical or electrophysiological neuropathy: comparison with age- and gender-matched controls [published online June 2, 2020]. Rheumatol Int. doi:10.1007/s00296-020-04610-8

Read more:
SLE May Have Early Effect on Peripheral Nerve Function Before Electrophysiologic or Clinical Neuropathy Development - Rheumatology Advisor